With an over 270 million population, Indonesia remains an emerging medical market, supported by the surge of healthcare awareness demanded by the rising middle-income community. However, the country has faced chronic problems as the pandemic unveils shortcomings and an elevated sense of urgency to develop a more resilient healthcare system and innovations.
East Ventures, a pioneering and leading sector-agnostic venture capital firm in Indonesia, has again presented its signature women-centered forum: Women with Impact Forum, as part of the celebration of International Women’s Day on 8 March 2022. This virtual forum discussed “Women as Active Agents for Sustainable Development” with five key speakers from different industries, such as venture capital, tech startups, and social enterprises.
Welcoming the new year of 2022, East Ventures is taking this opportunity to look back and reflect on the year 2021. Just like the rest of the world, the COVID-19 pandemic has also severely impacted our ecosystem—not only Indonesia, but it also took a heavy toll on Singapore and other SEA countries as well.
Menyambut tahun 2022, East Ventures mengambil kesempatan ini untuk melihat kembali dan merefleksikan tahun 2021. Sama seperti di seluruh dunia, pandemi COVID-19 juga memberikan dampak yang sangat besar pada ekosistem kami—tidak hanya di Indonesia, namun juga Singapura dan negara-negara Asia Tenggara lainnya.
Indonesian healthtech company focusing on personalized screening and intervention Nalagenetics and the leading edtech company in Southeast Asia Ruangguru have been chosen as the Top 10 startup in the G20 Innovation League 2021, an international forum held at Sorrento, Italy, on October 9-10, 2021.
Last year, Nalagenetics won its 1st major contract from the Indonesian health ministry to distribute 1,000 genetic test kits in Papua & West Papua.
With this Pre Seed funding, Nalagenetics aims to create cost-effective genetic tests tailored to Asian populations, starting in Singapore and Indonesia.
